Artal Group S.A. Intellia Therapeutics, Inc. Transaction History

Artal Group S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$33.3 - $44.82 $35,864 - $48,271	1,077 Added 0.39%	276,077 $10.3 Million
Q3 2021 Nov 12, 2021	BUY	$132.37 - $176.78 $3.31 Million - $4.42 Million	25,000 Added 10.0%	275,000 $36.9 Million
Q4 2020 Feb 11, 2021	BUY	$18.83 - $63.53 $1.13 Million - $3.81 Million	60,000 Added 31.58%	250,000 $13.6 Million
Q3 2020 Nov 13, 2020	SELL	$17.47 - $24.93 $856,030 - $1.22 Million	-49,000 Reduced 20.5%	190,000 $3.78 Million
Q2 2020 Aug 14, 2020	BUY	$11.14 - $22.87 $2.66 Million - $5.47 Million	239,000 New	239,000 $5.02 Million
Q1 2020 May 14, 2020	SELL	$9.44 - $15.58 $1.89 Million - $3.11 Million	-199,700 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$10.43 - $17.67 $2.08 Million - $3.53 Million	199,700 New	199,700 $2.93 Million
Q4 2018 Feb 11, 2019	SELL	$11.39 - $27.13 $1.03 Million - $2.44 Million	-90,000 Closed	0 $0
Q1 2018 May 10, 2018	SELL	$19.43 - $34.95 $3.11 Million - $5.59 Million	-160,000 Reduced 64.0%	90,000 $1.9 Million
Q4 2017 Feb 09, 2018	BUY	$17.39 - $31.12 $1.3 Million - $2.33 Million	75,000 Added 42.86%	250,000 $4.81 Million
Q3 2017 Nov 08, 2017	BUY	$15.16 - $25.75 $2.65 Million - $4.51 Million	175,000	175,000 $4.35 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.